November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly reduced circulating transthyretin (TTR) protein levels in patients with ATTR amyloid cardiomyopathy, a progressive and fatal cause of heart failure, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov.

November 8, 2022 — Fujifilm Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the U.S.

November 7, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results that show evaluating patients with suspected CAD by applying advanced artificial intelligence (AI) to CCTA allows for more accurate non-invasive diagnosis, reduces unnecessary testing, and offers higher confidence in identifying patients needing treatment. 

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) devices to support adults with rapidly deteriorating or severe cardiogenic shock was feasible but did not improve clinical outcomes compared to people who received early conservative therapy, according to late-breaking clinical trial re


Discover the key features of cardiovascular structured reporting that drive adoption, including automated data flow, EHR integration, and customizability.


Nov. 4, 2022 — The American College of Cardiology and the American Heart Association have published a new guideline on the diagnosis and management of aortic disease, focusing on surgical intervention considerations, consistent imaging practices, genetic and familial screenings, and the importance of a multidisciplinary aortic team.

Subscribe Now